Mof for radiotherapy
AssigneeNode Pharma AS
InventorsSigurd ØIEN-ØDEGAARD, Erik MJÅLAND
Life of this patent
Estimating the term…
Abstract
The present invention relates to MOFs for use in radiotherapy. More particularly, the invention provides a particle comprising a MOF, optionally at least one targeting moiety and at least one radionuclide; a composition comprising said particle; said particle or composition for use as a medicament; said particle or composition for use in a method for the treatment of a proliferative disease; said particle or composition for use in a method for the treatment of a chronic inflammatory disease; and a kit comprising a particle comprising a MOF, an optional targeting moiety, and a radionuclide cation.
Claims16
A particle comprising
- a MOF, wherein the MOF comprises
- a repeating three-dimensional network of inorganic monomers and organic monomers, forming pores, and
- at least one free functional group that extends into a pore, wherein the functional group is selected from the group consisting of carboxylic acid, carboxylate, hydroxyl, sulfonic acid, sulfonate, sulfhydryl, primary amines, secondary amines, and combinations thereof;
- optionally at least one targeting moiety connected to the particle on an external surface of the particle;
- and
- at least one radionuclide, wherein the at least one radionuclide is selected from the group consisting of radium-223, radium-224, radium-225, bismuth-212, bismuth-213, lead-212, actinium-225, thorium-227, terbium-149 and terbium-161:
- and wherein the at least one radionuclide is located in at least one of the pores.
A kit comprising,
- in a first container,
- a particle comprising
- a MOF, wherein the MOF comprises
- a repeating three-dimensional network of inorganic monomers and organic monomers, forming pores, and
- at least one free functional group that extends into a pore, wherein the functional group is selected from the group consisting of carboxylic acid, carboxylate, hydroxyl, sulfonic acid, sulfonate, sulfhydryl, primary amines, secondary amines, and combinations thereof;
- optionally at least one targeting moiety connected to the particle on an external surface of the particle;
- and
- and in a second container,
- a radionuclide, wherein the radionuclide is selected from the group consisting of radium-223, radium-224, radium-225, bismuth-212, bismuth-213, lead-212, actinium-225, thorium-227, terbium-149 and terbium-161, or a radionuclide generating any one of radium-223, radium-224, radium-225, bismuth-212, bismuth-213, lead-212, actinium-225, thorium-227, terbium-149 and terbium-161 as a daughter.
Dependencies are inferred from the claim text.